Cresset Discovery accelerates optimization of METTL3 inhibitor

Cresset Discovery has delivered a highly efficient digital workflow combining their molecular modeling expertise with Cresset technology to accelerate discovery, design and optimization of a METTL3 inhibitor. Working with Epics Therapeutics, the workflow combines scaffold hopping, in silico design and prioritization together with Epic’s medicinal chemistry team to drive efficient hit discovery and optimization, enabling progression towards a drug development candidate.

Please check out the full article on Cresset’s website.